Increasing evidence from mostly preclinical studies indicates that the gut microbiome modulates brain development and function across the lifespan. This pinpoints the microbiota-gut-brain axis as a potential target for influencing mood and behaviour, such as anxiety and depression, as well as preventing or treating brain-related diseases, including Parkinson’s disease, Alzheimer’s disease, schizophrenia and autism.
Currently, one of the biggest challenges is the translation of these insights into the clinical context. The first edition of MIND, MOOD & MICROBES in 2016 highlighted some challenges, such as limited suitable and clinically-relevant biomarkers, heterogeneous patient populations, and methodological discrepancies. A further complicating factor is that the fields of expertise involved are not closely related; microbial, neurological and psychiatric experts use different types of jargon, definitions and methodologies. To avoid overpromising of potential deliverables of this fascinating research field, it is essential that an interdisciplinary approach is stimulated.
MIND, MOOD & MICROBES – the 2nd International Conference on Microbiota-Gut-Brain Axis – will bring together academics, healthcare professionals, and industry partners from diverse and complimentary fields of expertise to accelerate the translation of research breakthroughs into professional and clinical practice.